Active	Status	Sponsor type	Region	Phase	Filter
17 Active 0 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

17 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Voskuhl, Gene W
NCT05565729: A Phase I Study of LY3471851 in Healthy Participants	Completed	1	41	US	LY3471851, NKTR-358, Placebo, Levocetirizine	Nektar Therapeutics, Eli Lilly and Company	Healthy	02/23	02/23
NCT05602675: A Drug Interaction Study of LY3871801 in Healthy Participants	Completed	1	39	US	LY3871801, Methotrexate, Warfarin, Dextromethorphan, Midazolam, Repaglinide	Eli Lilly and Company	Healthy	03/23	03/23
NCT05644353: A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants	Completed	1	450	US	Mirikizumab, LY3074828	Eli Lilly and Company	Healthy	05/23	05/23
NCT06132126: A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus	Completed	1	66	US	LY3938577, Placebo, Insulin degludec	Eli Lilly and Company	Healthy, Type 2 Diabetes Mellitus	06/24	06/24
NCT05295940: A Study of LY3841136 in Healthy and Overweight Participants	Completed	1	148	US	LY3841136, Placebo	Eli Lilly and Company	Obesity, Healthy	01/24	01/24
NCT06557356: A Study of LY3532226 in Participants With Obesity	Active, not recruiting	1	105	US, RoW	LY3532226, Placebo	Eli Lilly and Company	Obesity	05/25	05/25
NCT04451408: A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants	Completed	1	139	Japan, US	LY3372993, Placebo	Eli Lilly and Company	Alzheimer Disease, Healthy	11/24	11/24
NCT06641037: A Study of LY3866288 in Healthy Participants	Completed	1	15	US	LY3866288	Eli Lilly and Company	Healthy	12/24	12/24
NCT06916065: A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity	Not yet recruiting	1	188	US	Eloralintide and Tirzepatide, LY3841136, Eloralintide	Eli Lilly and Company	Overweight, Obesity	12/25	12/25
NCT06516913: A Study of Subcutaneous Injection in Healthy Participants	Completed	N/A	32	US	Syringe Pump	Eli Lilly and Company	Healthy	09/24	09/24
Bowie, Archie
NCT06345066: A Study of LY3841136 in Overweight and Obese Participants	Recruiting	1	96	US	Tirzepatide, LY3841136, Placebo	Eli Lilly and Company	Obesity, Overweight	10/25	10/25
NCT06440980: A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight	Active, not recruiting	1	508	US	Orforglipron, LY3502970	Eli Lilly and Company	Healthy, Obese, Overweight, Obesity	05/25	05/25
NCT06606106: A Study of LY3537031 in Overweight, Obese, and Healthy Participants	Recruiting	1	230	US	LY3537031, Placebo	Eli Lilly and Company	Healthy, Obesity	07/26	07/26
FPAB, NCT06690996: A Study of LY4005130 in Healthy Participants	Recruiting	1	140	US	LY4005130, Placebo	Eli Lilly and Company	Healthy	01/26	01/26
NCT06709820: A Study of LY4060874 in Healthy Participants	Recruiting	1	132	US, RoW	LY4060874, Placebo	Eli Lilly and Company	Healthy Participants	12/25	12/25
NCT06890611: A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants	Recruiting	1	100	US	Bimagrumab, LY3985863, BYM338, VER201, Tirzepatide, LY3298176, Bimagrumab + Tirzepatide Coformulation, LY900042	Eli Lilly and Company	Healthy	11/25	11/25
NCT06945419: A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes	Not yet recruiting	1	165	US, RoW	LY4086940, Placebo	Eli Lilly and Company	Healthy, Overweight, Obesity, Type 2 Diabetes	04/26	04/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Voskuhl, Gene W
NCT05565729: A Phase I Study of LY3471851 in Healthy Participants	Completed	1	41	US	LY3471851, NKTR-358, Placebo, Levocetirizine	Nektar Therapeutics, Eli Lilly and Company	Healthy	02/23	02/23
NCT05602675: A Drug Interaction Study of LY3871801 in Healthy Participants	Completed	1	39	US	LY3871801, Methotrexate, Warfarin, Dextromethorphan, Midazolam, Repaglinide	Eli Lilly and Company	Healthy	03/23	03/23
NCT05644353: A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants	Completed	1	450	US	Mirikizumab, LY3074828	Eli Lilly and Company	Healthy	05/23	05/23
NCT06132126: A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus	Completed	1	66	US	LY3938577, Placebo, Insulin degludec	Eli Lilly and Company	Healthy, Type 2 Diabetes Mellitus	06/24	06/24
NCT05295940: A Study of LY3841136 in Healthy and Overweight Participants	Completed	1	148	US	LY3841136, Placebo	Eli Lilly and Company	Obesity, Healthy	01/24	01/24
NCT06557356: A Study of LY3532226 in Participants With Obesity	Active, not recruiting	1	105	US, RoW	LY3532226, Placebo	Eli Lilly and Company	Obesity	05/25	05/25
NCT04451408: A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants	Completed	1	139	Japan, US	LY3372993, Placebo	Eli Lilly and Company	Alzheimer Disease, Healthy	11/24	11/24
NCT06641037: A Study of LY3866288 in Healthy Participants	Completed	1	15	US	LY3866288	Eli Lilly and Company	Healthy	12/24	12/24
NCT06916065: A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity	Not yet recruiting	1	188	US	Eloralintide and Tirzepatide, LY3841136, Eloralintide	Eli Lilly and Company	Overweight, Obesity	12/25	12/25
NCT06516913: A Study of Subcutaneous Injection in Healthy Participants	Completed	N/A	32	US	Syringe Pump	Eli Lilly and Company	Healthy	09/24	09/24
Bowie, Archie
NCT06345066: A Study of LY3841136 in Overweight and Obese Participants	Recruiting	1	96	US	Tirzepatide, LY3841136, Placebo	Eli Lilly and Company	Obesity, Overweight	10/25	10/25
NCT06440980: A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight	Active, not recruiting	1	508	US	Orforglipron, LY3502970	Eli Lilly and Company	Healthy, Obese, Overweight, Obesity	05/25	05/25
NCT06606106: A Study of LY3537031 in Overweight, Obese, and Healthy Participants	Recruiting	1	230	US	LY3537031, Placebo	Eli Lilly and Company	Healthy, Obesity	07/26	07/26
FPAB, NCT06690996: A Study of LY4005130 in Healthy Participants	Recruiting	1	140	US	LY4005130, Placebo	Eli Lilly and Company	Healthy	01/26	01/26
NCT06709820: A Study of LY4060874 in Healthy Participants	Recruiting	1	132	US, RoW	LY4060874, Placebo	Eli Lilly and Company	Healthy Participants	12/25	12/25
NCT06890611: A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants	Recruiting	1	100	US	Bimagrumab, LY3985863, BYM338, VER201, Tirzepatide, LY3298176, Bimagrumab + Tirzepatide Coformulation, LY900042	Eli Lilly and Company	Healthy	11/25	11/25
NCT06945419: A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes	Not yet recruiting	1	165	US, RoW	LY4086940, Placebo	Eli Lilly and Company	Healthy, Overweight, Obesity, Type 2 Diabetes	04/26	04/26